MiMedx Group (NASDAQ:MDXG) Issues Quarterly Earnings Results

MiMedx Group (NASDAQ:MDXG) announced its quarterly earnings data on Wednesday. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.02), FiscalAI reports. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The firm had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million.

Here are the key takeaways from MiMedx Group’s conference call:

• Sanara MedTech acquisition: MiMedx agreed to acquire Sanara for $35 per share, creating a combined regenerative medicine company expected to generate more than $400 million in 2027 revenue, double-digit growth, over 20% adjusted EBITDA margins, and at least $20 million in annual cost synergies.
• Surgical momentum remained strong: Second-quarter surgical revenue increased 15% year over year, with broad-based growth across the portfolio, while the Sanara deal is expected to expand MiMedx’s surgical addressable market by approximately $4 billion.
• Wound care showed early stabilization: Wound revenue rose 11% sequentially and volume increased 22%, including 44% sequential growth in wound care centers, but revenue remained down 61% year over year because of substantially reduced Medicare reimbursement and ongoing administrative challenges.
• Second-quarter profitability deteriorated: Net sales fell 35% year over year to $64 million, adjusted EBITDA was negative $8 million, and gross margin declined to 69%; results included an additional $5 million bad-debt charge tied mainly to private-office accounts.
• Financing and outlook: MiMedx reiterated 2026 standalone revenue guidance of $260 million to $290 million and expects adjusted EBITDA to approach breakeven, while financing the Sanara acquisition with a $300 million term loan carrying interest at SOFR plus 6.25%.

MiMedx Group Trading Down 3.4%

Shares of MiMedx Group stock traded down $0.14 on Thursday, hitting $4.08. The stock had a trading volume of 3,353,638 shares, compared to its average volume of 1,292,236. The stock has a 50 day moving average of $3.90 and a 200 day moving average of $4.25. MiMedx Group has a twelve month low of $3.03 and a twelve month high of $7.99. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The firm has a market capitalization of $608.46 million, a P/E ratio of 20.43 and a beta of 1.45.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Citizens Jmp decreased their price target on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings lowered MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Wall Street Zen cut MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Craig Hallum lowered their target price on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, MiMedx Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its holdings in MiMedx Group by 1.4% in the first quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock valued at $7,466,000 after purchasing an additional 13,629 shares during the period. AQR Capital Management LLC lifted its holdings in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after buying an additional 4,296 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in MiMedx Group during the 1st quarter worth about $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after buying an additional 4,049 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock valued at $9,355,000 after buying an additional 596,016 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

Trending Headlines about MiMedx Group

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: MiMedx agreed to acquire Sanara MedTech in a cash-and-stock transaction valued at approximately $350 million, or $35 per Sanara share. Management expects the combination to nearly double surgical revenue, expand gross and adjusted EBITDA margins, and generate more than $20 million in annual run-rate cost synergies. MIMEDX to Acquire Sanara MedTech
• Positive Sentiment: Following the planned Sanara transaction, MiMedx outlined 2027 revenue of well above $400 million and an adjusted EBITDA margin exceeding 20%, signaling significant expected scale and profitability benefits. MiMedx 2027 Outlook
• Positive Sentiment: MiMedx reiterated standalone fiscal 2026 revenue guidance of $260 million to $290 million. The midpoint of $275 million is modestly above the analyst consensus of $269.8 million. MiMedx Second-Quarter Results
• Neutral Sentiment: Second-quarter revenue was $64.36 million, slightly ahead of expectations of $63.46 million. However, the company reported a $0.05 per-share loss versus the anticipated $0.03 loss, creating a mixed near-term earnings signal. MiMedx Q2 Earnings Snapshot
• Negative Sentiment: The EPS shortfall may be weighing on the stock, while the Sanara acquisition introduces execution, integration, financing and potential shareholder-dilution risks before the projected synergies are realized. MiMedx Q2 Earnings Call Transcript

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.